DJIA 16,058.15 -469.88 -2.84%
NASDAQ 4,636.11 -140.40 -2.94%
S&P 500 1,913.85 -58.33 -2.96%
market minute promo

Amgen (NASDAQ: AMGN)

147.46 -4.32 (-2.85%)

REAL-TIME: Last trade at

Extended Hours: $148.79 $1.33 (0.90%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

AMGN $147.46 -2.85%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $149.23
Previous Close $151.78
Daily Range $146.95 - $150.99
52-Week Range $127.67 - $181.81
Market Cap $111.8B
P/E Ratio 20.10
Dividend (Yield) $3.16 (2.1%)
Ex-Dividend Date
Dividend Pay Date
08/13/15
09/08/15
Volume 5,418,705
Average Daily Volume 4,118,952
Current FY EPS $9.72

Sector

Healthcare

Industry

Drug Makers

Amgen (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

News & Commentary

A Word of Advice for Amgen: Objects in the Mirror Are Closer Than They Appear

Amgen's multiple myeloma drug Kyprolis recently had its label expanded, but sales growth is no guarantee, especially with a Johnson & Johnson experimental drug waiting in the wings.

26 Stocks For September 2015

Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor

Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept

Amgen Poised To Dominate A $32 Billion Biosimilar Market

Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.

How Amgen Can Disrupt the Market for Cholesterol Drugs

Time to Buy Amgen After Newly Approved Drug?

Premarket Biotech Digest: Geron EDP Today, Repatha Approval, Mylan Perrigo Deal

Aug. 28 Premarket Briefing: 10 Things You Should Know

See More AMGN News...

AMGN's Top Competitors

AMGN $147.46 (-2.85%)
Current stock: AMGN
GILD $101.49 (-3.41%)
Current stock: GILD
CELG $115.46 (-2.22%)
Current stock: CELG
$0.00 (0.00%)
Current stock: